The biological activity of auranofin: implications for novel treatment of diseases

[1]  W. Buchanan,et al.  Auranofin. , 2020, British journal of rheumatology.

[2]  M. Arkin,et al.  A high throughput drug screen for Entamoeba histolytica identifies a new lead and target , 2012, Nature Medicine.

[3]  A. Tramontano,et al.  Investigation of a potential mechanism for the inhibition of SmTGR by Auranofin and its implications for Plasmodium falciparum inhibition. , 2012, Biochemical and biophysical research communications.

[4]  S. Shioda,et al.  Auranofin protects against cocaine-induced hepatic injury through induction of heme oxygenase-1. , 2011, The Journal of toxicological sciences.

[5]  S. Berners‐Price,et al.  Gold compounds as therapeutic agents for human diseases. , 2011, Metallomics : integrated biometal science.

[6]  A. Mai,et al.  Gold drug auranofin restricts the viral reservoir in the monkey AIDS model and induces containment of viral load following ART suspension , 2011, AIDS.

[7]  M. Kizaki,et al.  The gold compound auranofin induces apoptosis of human multiple myeloma cells through both down-regulation of STAT3 and inhibition of NF-κB activity. , 2011, Leukemia research.

[8]  Margaret S. Lee,et al.  Auranofin Protects against Anthrax Lethal Toxin-Induced Activation of the Nlrp1b Inflammasome , 2010, Antimicrobial Agents and Chemotherapy.

[9]  X. Rabasseda.  A report from the XVIII International AIDS Conference. (July 18-23, 2010-Vienna, Austria). , 2010, Drugs of today.

[10]  H. Youn,et al.  TBK1-targeted suppression of TRIF-dependent signaling pathway of toll-like receptor 3 by auranofin , 2010, Archives of pharmacal research.

[11]  A. Guevara-Flores,et al.  In vitro killing action of auranofin on Taenia crassiceps metacestode (cysticerci) and inactivation of thioredoxin–glutathione reductase (TGR) , 2010, Parasitology Research.

[12]  K. Brown,et al.  Mitochondrial respiratory chain involvement in peroxiredoxin 3 oxidation by phenethyl isothiocyanate and auranofin , 2010, FEBS letters.

[13]  D. Meyer,et al.  HIV therapeutic possibilities of gold compounds , 2010, BioMetals.

[14]  A. Miele,et al.  Inhibition of Schistosoma mansoni Thioredoxin-glutathione Reductase by Auranofin , 2009, The Journal of Biological Chemistry.

[15]  Geneviève Boucher,et al.  HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation , 2009, Nature Medicine.

[16]  D. Pearson,et al.  IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. , 2009, Neuro-oncology.

[17]  R. Jerala,et al.  Free Thiol Group of MD-2 as the Target for Inhibition of the Lipopolysaccharide-induced Cell Activation* , 2009, The Journal of Biological Chemistry.

[18]  J. Ward,et al.  The Heart Is an Early Target of Anthrax Lethal Toxin in Mice: A Protective Role for Neuronal Nitric Oxide Synthase (nNOS) , 2009, PLoS pathogens.

[19]  W. Self,et al.  Inhibition of Selenium Metabolism in the Oral Pathogen Treponema denticola , 2009, Journal of bacteriology.

[20]  R. Levine,et al.  Auranofin disrupts selenium metabolism in Clostridium difficile by forming a stable Au–Se adduct , 2009, JBIC Journal of Biological Inorganic Chemistry.

[21]  K. Brown,et al.  The thioredoxin reductase inhibitor auranofin triggers apoptosis through a Bax/Bak-dependent process that involves peroxiredoxin 3 oxidation. , 2008, Biochemical pharmacology.

[22]  C. Dani,et al.  The Influence of Auranofin, a Clinically Established Antiarthritic Gold Drug, on Bone Metabolism: Analysis of Its Effects on Human Multipotent Adipose‐Derived Stem Cells, Taken as a Model , 2008, Chemistry & biodiversity.

[23]  R. Nelson,et al.  Arsenic trioxide and auranofin inhibit selenoprotein synthesis: implications for chemotherapy for acute promyelocytic leukaemia , 2008, British journal of pharmacology.

[24]  Anna V. Protasio,et al.  Platyhelminth Mitochondrial and Cytosolic Redox Homeostasis Is Controlled by a Single Thioredoxin Glutathione Reductase and Dependent on Selenium and Glutathione* , 2008, Journal of Biological Chemistry.

[25]  W. Kean,et al.  Clinical pharmacology of gold , 2008, Inflammopharmacology.

[26]  N. Ha,et al.  Auranofin inhibits overproduction of pro-inflammatory cytokines, cyclooxygenase expression and PGE2 production in macrophages , 2008, Archives of pharmacal research.

[27]  A. Casini,et al.  New uses for old drugs. Auranofin, a clinically established antiarthritic metallodrug, exhibits potent antimalarial effects in vitro: Mechanistic and pharmacological implications , 2008, FEBS letters.

[28]  Nam‐Hoon Kim,et al.  Auranofin blocks interleukin‐6 signalling by inhibiting phosphorylation of JAK1 and STAT3 , 2007, Immunology.

[29]  C. Chong,et al.  New uses for old drugs , 2007, Nature.

[30]  E. Davioud‐Charvet,et al.  Thioredoxin Glutathione Reductase from Schistosoma mansoni: An Essential Parasite Enzyme and a Key Drug Target , 2007, PLoS medicine.

[31]  V. Gandin,et al.  Inhibition of thioredoxin reductase by auranofin induces apoptosis in cisplatin-resistant human ovarian cancer cells. , 2007, Free radical biology & medicine.

[32]  K. Miyake,et al.  Auranofin, as an anti-rheumatic gold compound, suppresses LPS-induced homodimerization of TLR4. , 2006, Biochemical and biophysical research communications.

[33]  R. Messer,et al.  Gold-induced reactive oxygen species (ROS) do not mediate suppression of monocytic mitochondrial or secretory function. , 2006, Toxicology in vitro : an international journal published in association with BIBRA.

[34]  A. Thompson,et al.  Giardia and Cryptosporidium join the 'Neglected Diseases Initiative'. , 2006, Trends in parasitology.

[35]  R. Chen,et al.  TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer. , 2006, Cancer research.

[36]  Ira Pastan,et al.  Identification of proangiogenic genes and pathways by high-throughput functional genomics: TBK1 and the IRF3 pathway. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[37]  M. Valko,et al.  Free radicals, metals and antioxidants in oxidative stress-induced cancer. , 2006, Chemico-biological interactions.

[38]  S. Park,et al.  The role of p38 MAPK activation in auranofin‐induced apoptosis of human promyelocytic leukaemia HL‐60 cells , 2005, British journal of pharmacology.

[39]  J. B. Lewis,et al.  Anti-rheumatic gold compounds as sublethal modulators of monocytic LPS-induced cytokine secretion. , 2005, Toxicology in vitro : an international journal published in association with BIBRA.

[40]  J. Chung,et al.  Heat shock-induced matrix metalloproteinase (MMP)-1 and MMP-3 are mediated through ERK and JNK activation and via an autocrine interleukin-6 loop. , 2004, The Journal of investigative dermatology.

[41]  I. S. Kim,et al.  Auranofin induces apoptosis and when combined with retinoic acid enhances differentiation of acute promyelocytic leukaemia cells in vitro , 2004, British journal of pharmacology.

[42]  M. Karin,et al.  The IKK/NF-κB activation pathway—a target for prevention and treatment of cancer , 2004 .

[43]  Jinsong Liu,et al.  Intrinsic oxidative stress in cancer cells: a biochemical basis for therapeutic selectivity , 2004, Cancer Chemotherapy and Pharmacology.

[44]  F. Bach,et al.  Heme oxygenase-1: unleashing the protective properties of heme. , 2003, Trends in immunology.

[45]  R. Bicknell,et al.  Hypoxia and oxidative stress in breast cancer: Oxidative stress: its effects on the growth, metastatic potential and response to therapy of breast cancer , 2001, Breast Cancer Research.

[46]  Alberto Mantovani,et al.  Inflammation and cancer: back to Virchow? , 2001, The Lancet.

[47]  R. Gaynor,et al.  Therapeutic potential of inhibition of the NF-kappaB pathway in the treatment of inflammation and cancer. , 2001, The Journal of clinical investigation.

[48]  D. Carucci,et al.  Malaria research in the post-genomic era. , 2000, Parasitology today.

[49]  A. Griffioen,et al.  Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation. , 2000, Pharmacological reviews.

[50]  K. Jeon,et al.  Thiol-Reactive Metal Compounds Inhibit NF-κB Activation by Blocking IκB Kinase1 , 2000, The Journal of Immunology.

[51]  K. Jeon,et al.  Thiol-reactive metal compounds inhibit NF-kappa B activation by blocking I kappa B kinase. , 2000, Journal of immunology.

[52]  M. Kondo,et al.  Auranofin inhibits interleukin-1beta-induced transcript of cyclooxygenase-2 on cultured human synoviocytes. , 1999, European journal of pharmacology.

[53]  Jones Js,et al.  Life in the 21st century - a vision for all. , 1998 .

[54]  S. Tonegawa,et al.  Targeted gene deletion of heme oxygenase 2 reveals neural role for carbon monoxide. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[55]  U. Brodin,et al.  Auranofin is safe and superior to placebo in elderly-onset rheumatoid arthritis. , 1997, British journal of rheumatology.

[56]  G. Mccollum,et al.  Thioredoxin reductase activity is decreased by selenium deficiency. , 1997, Biochemical and biophysical research communications.

[57]  K. Ohuchi,et al.  Dual effects of auranofin on prostaglandin E2 production by rat peritoneal macrophages. , 1997, European journal of pharmacology.

[58]  J. Drazen,et al.  Antiinflammatory potential of lipoxygenase-derived eicosanoids: a molecular switch at 5 and 15 positions? , 1997, The Journal of clinical investigation.

[59]  Anthony S. Fauci,et al.  Host factors and the pathogenesis of HIV-induced disease , 1996, Nature.

[60]  J. Masci,et al.  Treatment of HIV associated psoriatic arthritis with oral gold. , 1996, The Journal of rheumatology.

[61]  F. Barkhof,et al.  A phase II trial of anti-CD4 antibodies in the treatment of multiple sclerosis , 1996, Multiple sclerosis.

[62]  D. Blake,et al.  Inactivation of tissue inhibitor of metalloproteinase‐1 by peroxynitrite , 1996, FEBS letters.

[63]  K. Papp,et al.  Systemic gold therapy. , 1991, Clinics in dermatology.

[64]  J. Ziegler,et al.  The gold complexes. , 1990, Bailliere's clinical rheumatology.

[65]  W. Kean.  Intramuscular versus oral gold therapy. , 1990, Bailliere's clinical rheumatology.

[66]  H. Morton,et al.  Quantitative relationship of Treponema denticola to severity of periodontal disease , 1988, Infection and immunity.

[67]  W. Buchanan,et al.  The history of gold therapy in rheumatoid disease. , 1985, Seminars in arthritis and rheumatism.

[68]  S. Donovan,et al.  Intestinal uptake and metabolism of auranofin, a new oral gold-based antiarthritis drug. , 1984, Science.

[69]  D E Griswold,et al.  Biologic actions and pharmacokinetic studies of auranofin. , 1983, The American journal of medicine.

[70]  M. Aon,et al.  THIOREDOXIN REDUCTASE 2 IS ESSENTIAL FOR KEEPING LOW LEVELS OF H 2 O 2 EMISSION FROM ISOLATED HEART MITOCHONDRIA , 2011 .

[71]  Nam‐Hoon Kim,et al.  Auranofin, a gold(I)-containing antirheumatic compound, activates Keap1/Nrf2 signaling via Rac1/iNOS signal and mitogen-activated protein kinase activation. , 2010, Journal of pharmacological sciences.

[72]  R. Saura,et al.  Inhibition of neovascularization in vivo by gold compounds , 2004, Rheumatology International.

[73]  M. Karin,et al.  The IKK/NF-kappaB activation pathway-a target for prevention and treatment of cancer. , 2004, Cancer letters.

[74]  B. Baguley,et al.  Role of lipophilicity in determining cellular uptake and antitumour activity of gold phosphine complexes , 2000, Cancer Chemotherapy and Pharmacology.

[75]  B. Arnason,et al.  Immunologic therapy of multiple sclerosis. , 1999, Annual review of medicine.

[76]  Y. Niida,et al.  Oxidative stress causes enhanced endothelial cell injury in human heme oxygenase-1 deficiency. , 1999, The Journal of clinical investigation.

[77]  F. Shabani,et al.  The oxidative inactivation of tissue inhibitor of metalloproteinase-1 (TIMP-1) by hypochlorous acid (HOCI) is suppressed by anti-rheumatic drugs. , 1998, Free radical research.

[78]  J. Jones,et al.  Life in the 21st century - a vision for all. , 1998, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

[79]  W. Buchanan,et al.  Disease-modifying drugs series editor : T. PULLAR AURANOFIN , 1997 .